Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.


Related Content

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
FDA To Update Quality Metrics Guidance
Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say
FDA Guidance On Health Care Economic Data Is Coming In 2015
Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
FDA’s Temple: Better Meta-Analyses Needed Ahead Of Agency Guidance
FDA Will Allow ANDA Corrections … Until 10 Minor Deficiencies Found
FDA Wrangles With Generic Exclusivity, Looks To Courts For Direction
Adaptive Trials Could Have A Steep Regulatory Learning Curve


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts